[
  {
    "text": "1.2",
    "bbox": [
      110,
      80,
      138,
      93
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
    "bbox": [
      179,
      80,
      1000,
      93
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "China.",
    "bbox": [
      179,
      96,
      227,
      108
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.3",
    "bbox": [
      110,
      112,
      138,
      125
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
    "bbox": [
      179,
      112,
      1000,
      125
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
    "bbox": [
      179,
      128,
      1000,
      141
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
    "bbox": [
      180,
      145,
      1000,
      157
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
    "bbox": [
      180,
      161,
      1000,
      173
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.4",
    "bbox": [
      110,
      176,
      138,
      188
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
    "bbox": [
      179,
      192,
      1000,
      205
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
    "bbox": [
      179,
      225,
      1000,
      237
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
    "bbox": [
      179,
      240,
      1000,
      254
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
    "bbox": [
      179,
      257,
      1000,
      269
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
    "bbox": [
      179,
      274,
      765,
      284
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.5",
    "bbox": [
      110,
      288,
      138,
      301
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
    "bbox": [
      179,
      288,
      1000,
      301
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
    "bbox": [
      179,
      305,
      1000,
      318
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
    "bbox": [
      178,
      320,
      1000,
      334
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
    "bbox": [
      180,
      337,
      1000,
      349
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
    "bbox": [
      178,
      351,
      1000,
      366
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
    "bbox": [
      180,
      369,
      1000,
      381
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "to be determined by CC-Pharming.",
    "bbox": [
      179,
      383,
      436,
      398
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.5",
    "bbox": [
      110,
      400,
      138,
      412
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
    "bbox": [
      179,
      400,
      1000,
      413
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "2.0",
    "bbox": [
      108,
      415,
      138,
      429
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Coordinators and Governance Terms",
    "bbox": [
      181,
      417,
      461,
      428
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "2.1",
    "bbox": [
      109,
      432,
      138,
      444
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
    "bbox": [
      179,
      432,
      1000,
      445
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
    "bbox": [
      179,
      449,
      1000,
      461
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Statement of Work.",
    "bbox": [
      180,
      465,
      323,
      476
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Master Joint Development Agreement iBio CC-Pharming",
    "bbox": [
      112,
      496,
      537,
      509
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Page 2 of 12",
    "bbox": [
      1000,
      496,
      1000,
      509
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: IBIO, INC., 8-K, 3/13/2020",
    "bbox": [
      135,
      1000,
      412,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.2",
    "bbox": [
      110,
      80,
      138,
      93
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other than",
    "bbox": [
      179,
      80,
      1000,
      93
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "China.",
    "bbox": [
      179,
      96,
      227,
      108
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.3",
    "bbox": [
      110,
      112,
      138,
      125
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-",
    "bbox": [
      179,
      112,
      1000,
      125
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding the",
    "bbox": [
      179,
      128,
      1000,
      141
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "definitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, construction",
    "bbox": [
      180,
      145,
      1000,
      157
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "supervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.",
    "bbox": [
      180,
      161,
      1000,
      173
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.4",
    "bbox": [
      110,
      176,
      138,
      188
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio's Technology and",
    "bbox": [
      179,
      176,
      1000,
      189
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "technical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business or",
    "bbox": [
      179,
      192,
      1000,
      205
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "scientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legal",
    "bbox": [
      179,
      208,
      1000,
      221
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "structure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio's double-digit",
    "bbox": [
      179,
      225,
      1000,
      237
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "percentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio's.",
    "bbox": [
      179,
      240,
      1000,
      254
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Technology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer services",
    "bbox": [
      179,
      257,
      1000,
      269
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "relevant to the evolving business and Product(s) of the collaborative venture.",
    "bbox": [
      179,
      274,
      765,
      284
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.5",
    "bbox": [
      110,
      288,
      138,
      301
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of the",
    "bbox": [
      179,
      288,
      1000,
      301
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "therapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transient.",
    "bbox": [
      179,
      305,
      1000,
      318
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "expression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,",
    "bbox": [
      178,
      320,
      1000,
      334
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "product and process development services, training, quality management system design, and clinical planning and regulatory consulting.",
    "bbox": [
      180,
      337,
      1000,
      349
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidate",
    "bbox": [
      178,
      351,
      1000,
      366
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "but will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such work",
    "bbox": [
      180,
      369,
      1000,
      381
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "to be determined by CC-Pharming.",
    "bbox": [
      179,
      383,
      436,
      398
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.5",
    "bbox": [
      110,
      400,
      138,
      412
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.",
    "bbox": [
      179,
      400,
      1000,
      413
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "2.0",
    "bbox": [
      108,
      415,
      138,
      429
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Coordinators and Governance Terms",
    "bbox": [
      181,
      417,
      461,
      428
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "2.1",
    "bbox": [
      109,
      432,
      138,
      444
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators will",
    "bbox": [
      179,
      432,
      1000,
      445
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "be responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to that",
    "bbox": [
      179,
      449,
      1000,
      461
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Statement of Work.",
    "bbox": [
      180,
      465,
      323,
      476
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Master Joint Development Agreement iBio CC-Pharming",
    "bbox": [
      112,
      496,
      537,
      509
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Page 2 of 12",
    "bbox": [
      1000,
      496,
      1000,
      509
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: IBIO, INC., 8-K, 3/13/2020",
    "bbox": [
      135,
      1000,
      412,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  }
]